文献速递白血病血栓与止血

帕纳替尼在费城染色体阳性白血病中的疗效与安全性:2期PACE试验最终5年结果

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
PubMed 文献 · Blood · 2018-03-22

2期PACE试验评估帕纳替尼起始剂量45 mg每日一次治疗449例对达沙替尼或尼洛替尼耐药/不耐受或携带BCR-ABL1T315I的慢性髓性白血病(CML)或费城染色体阳性急性淋巴细胞白血病(ALL)患者的疗效与安全性。本分析聚焦270例慢性期CML(CP-CML)患者,中位随访56.8个月,267例可评估患者中60%达到主要细胞遗传学缓解(MCyR)、40%达到主要分子学缓解(MMR)、24%达到4.5-log分子学缓解;缓解者5年维持MCyR的概率为82%,估计5年总生存率为73%。

要点

  • 267例可评估CP-CML患者中60%达MCyR、40%达MMR、24%达4.5-log分子学缓解。
  • 缓解者5年维持MCyR的概率为82%,估计5年总生存率为73%。
  • CP-CML患者动脉闭塞事件(AOE)累积发生率随时间增至31%,但暴露调整后新发AOE年发生率未随时间增加。

核心结论

  • 最终PACE结果证明,帕纳替尼在这组经重度治疗的CP-CML患者中提供持久且具有临床意义的缓解,且不受剂量下调影响。

研究设计与样本

  • 2期Ponatinib Ph+ ALL and CML Evaluation(PACE)试验,帕纳替尼起始剂量45 mg每日一次,纳入449例对达沙替尼或尼洛替尼耐药/不耐受或携带BCR-ABL1T315I的CML或费城染色体阳性ALL患者。
  • 本分析聚焦CP-CML患者(n=270),中位随访56.8个月。
  • 试验注册号NCT01207440。

主要发现

  • 267例可评估患者中,60%达到MCyR、40%达到MMR、24%达到4.5-log分子学缓解。
  • 缓解者5年维持MCyR的概率为82%。
  • 2013年10月实施剂量下调以降低AOE风险;达到MCyR或MMR的CP-CML患者中≥90%在选择性剂量下调后40个月维持缓解。
  • 估计5年总生存率为73%。
  • CP-CML患者最常见的治疗中出现的不良事件为皮疹(47%)、腹痛(46%)、血小板减少(46%)、头痛(43%)、皮肤干燥(42%)和便秘(41%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1T315I The pivotal phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant/intolerant to dasatinib or nilotinib, or with BCR-ABL1T315I This analysis focuses on chronic-phase CML (CP-CML) patients (n = 270) with 56.8-month median follow-up. Among 267 evaluable patients, 60%, 40%, and 24% achieved major cytogenetic response (MCyR), major molecular response (MMR), and 4.5-log molecular response, respectively. The probability of maintaining MCyR for 5 years was 82% among responders. Dose reductions were implemented in October 2013 to decrease the risk of arterial occlusive events (AOEs); ≥90% of CP-CML patients who had achieved MCyR or MMR maintained response 40 months after elective dose reductions. Estimated 5-year overall survival was 73%. In CP-CML patients, the most common treatment-emergent adverse events were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%), and constipation (41%). The cumulative incidence of AOEs in CP-CML patients increased over time to 31%, while the exposure-adjusted incidence of new AOEs (15.8 and 4.9 per 100 patient-years in years 1 and 5, respectively) did not increase over time. These final PACE results demonstrate ponatinib provides durable and clinically meaningful responses, irrespective of dose reductions, in this population of heavily pretreated CP-CML patients. This trial was registered at www.clinicaltrials.gov as #NCT01207440.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018. PMID: 29567798. doi:10.1182/blood-2016-09-739086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。